Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

Nine PDUFA dates on FDA’s agenda in September

Decision on Zevra’s arimoclomol follows positive AdCom vote

August 30, 2024 7:43 PM UTC

FDA has at least nine PDUFA dates on its agenda for September, including an Hsp70 inducer for a rare genetic disease that was given a thumbs up by an advisory committee in August. 

The Genetic Metabolic Diseases Advisory Committee voted 11-5 that arimoclomol from Zevra Therapeutics Inc. (NASDAQ:ZVRA) is effective in Niemann-Pick disease type C disease. Arimoclomol, an orally delivered Hsp70 inducer, led to a reduction in long-term disease progression in an open-label Phase II/III trial. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article